RMTI 最新10-Q变化
将 RMTI 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-08-13 与上一份 10-Q · 2026-05-07
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +14 | −6 | ~10 | 20 |
| 市场风险(第3项) | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 控制与程序 | 文字有新增/删除 | 0 | 0 | ~2 | 1 |
| 法律诉讼 | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 风险因素 | 公司称无重大变化(指向 10-K) | — | — | — | — |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):其他信息
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-08-13
and delivering high-quality product to our customers for use with their patients.
On July 1, 2026, we effected a one-for-ten reverse stock split of our common stock to regain compliance with the Nasdaq Capital Market's $1.00 minimum bid price requirement. All share and per-share amounts in this report have been retrospectively adjusted to reflect the split for all periods present…
Results of Operations for the Three Months Ended June 30, 2026 and 2025
During the three months ended June 30, 2026, net sales were $17.8 million compared to net sales of $16.1 million during the three months ended June 30, 2025. The increase of $1.7 million was primarily driven by $1.3 million of sales to new customers in the Western United States as well as additional…
Cost of sales for the three months ended June 30, 2026 was $14.5 million, resulting in gross profit of $3.2 million for the three months ended June 30, 2026, compared to cost of sales of $13.6 million and a gross profit of $2.5 million for the three months ended June 30, 2025. The gross profit incre…
相对上期删除的文字 · 来源:10-Q · 2026-05-07
Results of Operations for the Three Months Ended March 31, 2026 and 2025
During the three months ended March 31, 2026, net sales were $17.3 million compared to net sales of $18.9 million during the three months ended March 31, 2025. The decrease of $1.6 million was primarily due to a $3.9 million reduction in sales to DaVita, which included a $0.9 million price adjustmen…
Cost of sales for the three months ended March 31, 2026 was $14.4 million, resulting in gross profit of $2.9 million for the three months ended March 31, 2026, compared to cost of sales of $15.9 million and a gross profit of $3.0 million for the three months ended March 31, 2025. The gross profit de…
General and administrative expenses were $3.8 million for the three months ended March 31, 2026, compared to $3.7 million for the three months ended March 31, 2025. The increase of $0.1 million was driven by higher compensation expense.
As of March 31, 2026, we had approximately $23.9 million of cash, cash equivalents and investments available-for-sale, and net working capital of $27.1 million. Based on the currently available net working capital along with the expectation of management of its ability to execute on its operational …
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议